key: cord-0778859-kinoxwmx
authors: Balsara, Keki R.; Rahaman, Zakiur; Sandhaus, Emily; Hoffman, Jordan; Zalawadiya, Sandip; McMaster, William; Lindenfeld, Joann; Wigger, Mark; Absi, Tarek; Brinkley, Douglas M.; Menachem, Jonathan; Punnoose, Lynn; Sacks, Suzie; Schlendorf, Kelly; Shah, Ashish S.
title: Prioritizing heart transplantation during the COVID‐19 pandemic
date: 2021-06-16
journal: J Card Surg
DOI: 10.1111/jocs.15731
sha: 8fe9fbf62ce9c02fcf6109430bf17719631b1dfd
doc_id: 778859
cord_uid: kinoxwmx

BACKGROUND: Coronavirus disease 2019 (COVID‐19) has significantly impacted the healthcare landscape in the United States in a variety of ways including a nation‐wide reduction in operative volume. The impact of COVID‐19 on the availability of donor organs and the impact on solid organ transplant remains unclear. We examine the impact of COVID‐19 on a single, large‐volume heart transplant program. METHODS: A retrospective chart review was performed examining all adult heart transplants performed at a single institution between March 2020 and June 2020. This was compared to the same time frame in 2019. We examined incidence of primary graft dysfunction, continuous renal replacement therapy (CRRT) and 30‐day survival. RESULTS: From March to June 2020, 43 orthotopic heart transplants were performed compared to 31 performed during 2019. Donor and recipient demographics demonstrated no differences. There was no difference in 30‐day survival. There was a statistically significant difference in incidence of postoperative CRRT (9/31 vs. 3/43; p = .01). There was a statistically significant difference in race (23 W/8B/1AA vs. 30 W/13B; p = .029). CONCLUSION: We demonstrate that a single, large‐volume transplant program was able to grow volume with little difference in donor variables and clinical outcomes following transplant. While multiple reasons are possible, most likely the reduction of volume at other programs allowed us to utilize organs to which we would not have previously had access. More significantly, our growth in volume was coupled with no instances of COVID‐19 infection or transmission amongst patients or staff due to an aggressive testing and surveillance program.

The first confirmed case of COVID-19 in the state of Tennessee was on March 5, 2020. By June 30, 2020, the total number of confirmed cases in the state was 43,806. Over this same period of time, our total cardiac volume was 488 cases compare to 521 cases during March-June 2019. The most significant decrease in volume was seen in April 2020 where volume was reduced by nearly 30% compared to the previous year.

From March-June 2020, 43 total orthotopic heart transplants were performed. This includes three re-transplants and seven multiorgan transplants (6 heart/kidney; 1 heart/liver; 0 heart/lung). The average recipient age was 54.2 ± 13.9 years and 29 recipients were male and 14 were female. Thirty recipients were Caucasian. Thirteen recipients were African American. There were 11 blood type A recipients, seven blood type B recipients, one blood type AB recipient From March-June 2019, 31 total orthotopic heart transplants were performed. This includes three re-transplants and three multiorgan transplants (3 heart/kidney; 0 heart/liver; 0 heart/lung). The average recipient age was 47.5 ± 13.3 years and 18 recipients were male and 13 were female. Twenty-three patients were Caucasian. (Table 3) .

There was no evidence of acute, postoperative infection of any recipient with COVID-19 during this time period.

Heart transplantation remains the definitive therapy for patients with end stage heart disease. The number of heart transplants performed in the United States has gradually increased to approximately 3000/year over the past 20 years. 7 The recent past has seen the introduction of a variety of means by which the donor pool may increase including ex vivo support platforms, older donors and extended criteria donors.

However, much of the potential benefit of these advances have not been recognized in the past year due to a world-wide pandemic secondary to COVID-19. In the United States, more than nine-million individuals have been infected and nearly 250,000 individuals have died as a result of infection. 8 The impact of this pandemic on the healthcare landscape has yet to be fully realized but it is likely to be substantial. The late spring and early summer saw widespread mitigation attempts including the shuttering of schools, places of work and businesses. Initial uncertainty regarding the scale of infection, the need for healthcare resources and the availability of personal protective equipment prompted many centers to institute moratoriums on all non-emergent care. [9] [10] [11] Anecdotal evidence suggests that many individuals did not seek medical care for non-COVID related chronic illness and more still did not present for urgent/emergent care. In fact, a recent study examined 717,103 patients in the Society of Thoracic Surgeons Database who underwent cardiac surgery between January 2017 and June 2020. They observed a 53% reduction in the average monthly cardiac surgical volume with the onset of the pandemic including a 65% decrease in elective and 40% reduction in nonelective cases. Geographically, the hardest hit areas were the mid-Atlantic states with a 71% reduction in volume and the New England states with a 63% reduction. The Southeast, where our center is located, experienced a nearly 50% reduction in volume over this same period. There was also a 110% increase in the observed to expected operative mortality nationwide. 12 The impact of COVID-19 on solid organ transplant, particularly orthotopic heart transplant, remains unclear. Scientific Registry of Transplant Recipients data suggests that many programs in geographically hard-hit areas significantly reduced or stopped all solid organ transplants. 13 CRRT post-op 9 4

Note: There was a statistically significant difference in the incidence of continuous renal replacement therapy (CRRT) between the two groups (p = .01). Rejection at 30 days was defined as 2 R or greater at biopsy.

Abbreviations: ICU, intensive care unit; LOS, length of stay; PGD, primary graft dysfunction.

BALSARA ET AL.

At the height of the COVID lockdown between March and June 2020, we were able to increase our transplant volume by nearly 40%.

Our ability to do this is attributable to both nation-wide trends re- Much effort was invested in being fully transparent in the initiatives we were implementing to augment patient safety. The most compelling argument was our acknowledgment that the duration of COVID-19 was uncertain and that its impact on organ availability was unknown. With this knowledge, most patients elected to undergo transplant, recognizing that it was unclear when an additional opportunity might present itself.

As an institution, we were not immune to the impact of While there are no clear answers to these ethical considerations, we sought to find a delicate balance between access to care for the many as a result of the pandemic and specialized care for the few in need of a life-saving transplant.

In the final analysis, COVID-19 has dramatically affected all aspects of our lives. Perhaps nowhere has this been more readily apparent than in the healthcare space. In spite of that impact, we demonstrate that orthotopic heart transplants can continue to be performed safely. While we cannot deny that we potentially benefited from other programs' reduction in volume, what we have truly demonstrated is that a rigorous testing and surveillance program allows one to continue providing this life-saving therapy, while ensuring the health and safety of both patients and providers.

The operation: a human cardiac transplant: an interim report of a successful operation performed at Groote Schuur, Hospital, Cape Town

Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement

Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C

Fair allocation of scarce medical resources in the time of COVID-19

American Society of Anesthesiologists, Association of perioperative Registered Nurses, American Hospital Association. Joint statement: roadmap for resuming elective surgery after COVID 19 pandemic

ACC/AGA/HFSA/ISHLT/ACP advanced training statement on advanced heart failure and transplant cardiology (revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced hear failure and cardiac transplant): a report of the ACC competency management committee

A change of heart: preliminary results of the US 2018 adult heart allocation revision

World Health Organization. Coronavirus disease (COVID-19) pandemic

A framework for rationing of ventilators and critical care beds during COVID-19 pandemic

Donor and transplant candidate selection for solid organ transplantation during the COVID-19 pandemic

Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a by-proxy society recommendation consensus approach

The effect of COVID-19 on adult cardiac surgery in the United States: Analysis of the Society of Thoracic Surgeons adult cardiac surgery database

Scientific Registry of Transplant Recipients. COVID-19 changes to

Donor and recipient racial mismatch impacts thoracic organ transplant survival

The authors declare that there are no conflict of interests.

Keki R. Balsara https://orcid.org/0000-0002-3502-5705